Literature DB >> 22344193

Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.

Claire Schvartz1, Franck Bonnetain, Sandrine Dabakuyo, Mélanie Gauthier, Adèle Cueff, Sandrine Fieffé, Jean-Marie Pochart, Inna Cochet, Elodie Crevisy, Audrey Dalac, Dimitri Papathanassiou, Michel Toubeau.   

Abstract

CONTEXT: American Thyroid Association and European Thyroid Association guidelines cannot recommend for or against radioactive iodine (RAI) ablation after surgery in low-risk differentiated thyroid cancer (DTC) patients.
OBJECTIVES: The objective of the study was to assess the survival benefit of RAI for these patients.
DESIGN: We identified 1298 DTC patients at low risk treated between 1975 and 2005. Logistic regressions were used to identify variables associated to RAI and to calculate the propensity score to receive RAI after surgery. We compared overall survival (OS) and disease-free survival (DFS) according to RAI with the log-rank tests and univariate and multivariate Cox analyses. Analyses stratified on propensity score were also performed.
RESULTS: Median follow-up was 10.3 yr. Nine hundred eleven patients received RAI after surgery vs. 387 patients without RAI after surgery. Using univariate analysis, 10-yr OS was found to be 95.8% in patients without RAI after surgery vs. 94.6% in RAI after surgery (P = 0.006), and 10-yr DFS was found to be 93.1% vs. 88.7% (P = 0.001). All clinical factors except sex were significantly associated with RAI. Using multivariate Cox analyses, RAI was neither significantly nor independently associated with OS (P = 0.243) and DFS (P = 0.2659). After stratification on propensity score, Cox univariate analyses showed that OS did not differ according to RAI (P = 0.3524), with a hazard ratio for RAI of 0.75 (95% confidence interval 0.40-1.38). Similarly, DFS did not differ (P = 0.48) with a stratified univariate hazard ratio of 1.11 (95% confidence interval 0.73-1.70).
CONCLUSION: With a long-term follow-up of 10.3 yr, we failed to prove any survival benefit of RAI after surgery in a large cohort of low-risk DTC patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22344193     DOI: 10.1210/jc.2011-2512

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  60 in total

Review 1.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

Review 2.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 3.  Surgical management of papillary thyroid carcinoma: an overview.

Authors:  Paolo Miccoli; Sohail Bakkar
Journal:  Updates Surg       Date:  2017-04-12

4.  Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes?

Authors:  Colleen M Kiernan; Alexander A Parikh; Lee L Parks; Carmen C Solórzano
Journal:  J Am Coll Surg       Date:  2014-12-17       Impact factor: 6.113

Review 5.  Managing newly diagnosed thyroid cancer.

Authors:  Anna M Sawka; James D Brierley; Shereen Ezzat; David P Goldstein
Journal:  CMAJ       Date:  2013-10-07       Impact factor: 8.262

Review 6.  Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients.

Authors:  M G Castagna; S Cantara; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-06-27       Impact factor: 4.256

7.  Central compartment revision surgery for persistent or recurrent thyroid carcinoma: analysis of survival and complication rate.

Authors:  Gabriele Molteni; Marco Bonali; Francesco Mattioli; Michael Ghirelli; Matteo Fermi; Gaetano Ferri; Malagoli Andrea; Livio Presutti
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-10       Impact factor: 2.503

8.  Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients.

Authors:  F Nabhan; K Porter; L Senter; M D Ringel
Journal:  J Endocrinol Invest       Date:  2017-05-16       Impact factor: 4.256

9.  Disease severity and radioactive iodine use for thyroid cancer.

Authors:  M R Haymart; D G Muenz; A K Stewart; J J Griggs; M Banerjee
Journal:  J Clin Endocrinol Metab       Date:  2013-01-15       Impact factor: 5.958

Review 10.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.